Enzyme replacement therapy is available for the treatment of the following disorder –
**Core Concept**
Enzyme replacement therapy (ERT) is a treatment approach that involves administering a recombinant form of a deficient enzyme to patients with genetic disorders caused by enzyme deficiencies. This approach is particularly effective for conditions where a specific enzyme is lacking or not functioning properly, leading to the accumulation of toxic metabolites or the deficiency of essential substrates.
**Why the Correct Answer is Right**
The correct answer is lysosomal storage disorders, such as Gaucher disease, Fabry disease, and Pompe disease. These disorders result from the deficiency of specific lysosomal enzymes, leading to the accumulation of toxic substrates within the lysosome. ERT involves the administration of recombinant forms of these deficient enzymes, which helps to restore normal lysosomal function and reduce the accumulation of toxic substrates. This approach has been shown to be effective in improving symptoms and quality of life for patients with these conditions.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because enzyme replacement therapy is not typically used for the treatment of cystic fibrosis, which is caused by a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
**Option B:** This option is incorrect because enzyme replacement therapy is not a standard treatment for multiple sclerosis, which is an autoimmune disease affecting the central nervous system.
**Option C:** This option is incorrect because enzyme replacement therapy is not commonly used for the treatment of sickle cell disease, which is caused by a genetic mutation in the hemoglobin gene.
**Clinical Pearl / High-Yield Fact**
ERT is a targeted therapeutic approach that can significantly improve the quality of life for patients with specific genetic disorders. However, it is essential to note that ERT is not a cure for these conditions and may require ongoing administration to maintain therapeutic benefits.
**Correct Answer: D. Lysosomal storage disorders.**